医疗保健检测服务市场 - 全球产业规模、份额、趋势、机会及预测（按服务类型、产品类型、发展阶段、最终用户、地区和竞争格局划分，2021-2031年）

全球医疗检测服务市场预计将从 2025 年的 64.6 亿美元成长到 2031 年的 90.1 亿美元，复合年增长率为 5.71%。

该领域涵盖医疗设备和製药公司用于确保从研发到生产的整个流程中符合监管要求、产品安全和品质的生物分析和分析测试解决方案。市场成长趋势的主要驱动力是药物分子（尤其是生物製药）日益复杂，以及为降低营运成本而转向外包的策略转变。此外，日益严格的监管审查也是重要的成长引擎，迫使製造商满足严格的品质标准。美国食品药物管理局(FDA) 的《2024 年药品品质状况报告》也强调了这一点，该报告预测 2024 财年将进行 989 项药品品质保证测试，比上年度增长 27%。

然而，市场面临着管理复杂调查方法所需的专业人才短缺的严峻挑战。能够操作先进设备并解读复杂资料集的合格分析师人才储备有限，这给服务供应商造成了营运瓶颈，并导致人事费用上升。此外，维护认证实验室所需的大量资本投入进一步加剧了人才短缺问题，这可能会限制业务扩充性，并严重阻碍全球医疗检测行业的全面扩张。

市场驱动因素

全球慢性病和感染疾病的日益普及是全球医疗检测服务市场的主要驱动力。糖尿病、癌症和结核病等复杂疾病发病率的上升，促使公共卫生机构和製药公司对各种生物分析支持和诊断测试的需求不断增长，以加速治疗方法的研发。对于感染疾病，这种需求尤其迫切，因为快速监测和检测对于控制疫情传播和保护患者健康至关重要。世界卫生组织（世卫组织）在2024年10月发布的《2024年全球结核病报告》中指出，2023年全球将新增约820万例结核病病例，这将是自1995年全球进行结核病监测以来的最高数字。日益加重的疾病负担直接导致上市后监测和检验新治疗方法所需的临床试验检测增加。

同时，生物製药和生物相似药开发平臺的不断扩展正在改变检测服务产业的格局。与传统的小分子药物不同，单株抗体和细胞疗法等大分子治疗药物需要高度专业化、灵敏且昂贵的调查方法来评估其效力、纯度和免疫抗原性。这种转变迫使製造商将这些复杂的检测工作外包给配备先进设备的认证检测实验室。根据美国药物化学及相关技术协会 (DCAT) 于 2024 年 7 月发布的《创新记分卡》，美国 FDA 将在 2023 年核准17 种新的治疗性生技药品，占所有新药核准的 31%。这凸显了该产业向复杂分子药物研发的重大转变。领先服务供应商的业绩也反映了这一领域的经济影响。根据 Eurofins Scientific 于 2024 年 2 月发布的“2023 年全年业绩报告”，该公司报告总收入为 65.15 亿欧元，反映出工业界对外包分析测试活动的持续需求。

市场挑战

全球医疗检测服务市场发展面临的主要障碍之一是专业技术人员短缺。随着医疗设备和製药公司对先进生物分析和分析检测的需求不断增长，他们面临着能够操作这些先进技术的合格分析师严重短缺的问题。这种人才短缺导致营运效率下降，例如检体处理能力降低和交货时间延长。因此，服务供应商被迫限制新客户的接收并推迟计划进度，直接抑制了收入成长和市场扩张。

此外，招募和留住专业人员的高昂成本给实验室带来了日益沉重的财务负担。近期行业统计也印证了这项劳动力短缺问题。根据美国临床病理学会2024年的职缺调查，病理科的职缺率已高达28.5%，凸显了此关键检测领域劳动力短缺的严重性。如此高的职缺率阻碍了实验室充分利用其先进的基础设施和设备。如果没有足够的人员来支援业务扩张，检测服务提供者将无法满足不断增长的全球需求，从而有效地阻碍整个医疗检测行业的发展。

市场趋势

人工智慧 (AI) 的整合应用正在革新检查室工作流程，透过自动化复杂的影像分析和改进临床决策，提高诊断准确性。检查室越来越多地部署机器学习演算法来处理海量的病理学和放射学资料集，从而减少人为错误并识别传统方法常常遗漏的细微生物标记。这项技术变革正在加速智慧诊断工具的商业性化应用，并加快基于软体的医疗解决方案的监管核准流程。根据 MedTech Dive 杂誌 2024 年 10 月号一篇报导「过去十年人工智慧医疗设备数量激增」的文章，美国食品药物管理局(FDA) 在 2023 年核准了221 种人工智慧或机器学习驱动的医疗设备，这标誌着这些技术在临床应用中的检验显着增加。

同时，基因组学和精准医疗检测服务的蓬勃发展正将诊断的重点从广泛筛检转向个人化患者分析。与评估药物特性的标准生物分析检测不同，这种转变强调识别遗传风险，并指导针对特定患者的标靶治疗，尤其是在周产期护理和肿瘤学领域。为此，服务供应商正在扩展其服务范围，纳入能够提供更深入的临床见解并支援个人化治疗策略的先进分子诊断技术。这种强劲的需求也反映在近期的财务表现中。 Quest Diagnostics 在 2024 年 2 月发布的「2023 财年第四季及全年」报告中宣布，其营收实现了两位数成长，尤其是在包括遗传疾病检测和产前检测在内的先进临床领域，凸显了市场对专业精准检测日益增长的需求。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球医疗保健检测服务市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按服务项目（化学测试、微生物测试、毒性测试、稳定性测试等）
  • 依产品类型（抗病毒药物、HIV药物、生育药物、抗糖尿病药物、呼吸系统药物、抗凝血剂、医疗设备、药品包装、其他）
  • 依研发阶段（非临床、临床、生产）
  • 依最终用户（製药业、合约研究机构、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美医疗保健实验室服务市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲医疗保健实验室服务市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区医疗保健实验室服务市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲医疗保健实验室服务市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲医疗保健实验室服务市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球医疗保健实验室服务市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Eurofins Scientific（Ireland）Limited
• Thermo Fisher Scientific Inc.
• Microbac Laboratories, Inc.
• ARL Bio Pharma, Inc.
• EM Topco Limited
• Intertek Group plc
• Moderna, Inc.
• ZYUS Life Sciences Corp
• Alcami Corporation
• F. Hoffmann-La Roche Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Healthcare Testing Services Market is projected to expand from USD 6.46 Billion in 2025 to USD 9.01 Billion by 2031, reflecting a CAGR of 5.71%. This sector comprises bioanalytical and analytical testing solutions that medical device manufacturers and pharmaceutical companies utilize to guarantee regulatory compliance, product safety, and quality across the development and manufacturing spectrum. The market's upward trajectory is largely influenced by the growing intricacy of drug molecules, particularly biologics, alongside a strategic pivot toward outsourcing to lower operational expenses. Furthermore, intensified regulatory oversight serves as a crucial growth engine, forcing manufacturers to meet stringent quality benchmarks. This is evidenced by the U.S. Food and Drug Administration's FY2024 Report on the State of Pharmaceutical Quality, which noted 989 drug quality assurance inspections in fiscal year 2024, representing a 27% rise from the prior year.

However, the market encounters a substantial challenge regarding the scarcity of skilled professionals required to manage complex testing methodologies. The limited pool of qualified analysts capable of operating advanced instrumentation and interpreting intricate data sets creates operational bottlenecks and increases labor costs for service providers. This talent gap, exacerbated by the substantial capital investment needed to maintain accredited laboratories, restricts the scalability of operations and could significantly impede the broader expansion of the global healthcare testing sector.

Market Driver

The escalating global prevalence of chronic and infectious diseases acts as a major engine driving the Global Healthcare Testing Services Market. With the rising incidence of complex conditions like diabetes, cancer, and tuberculosis, public health entities and pharmaceutical firms are increasing their requirements for extensive bioanalytical support and diagnostic testing to speed up treatment creation. This necessity is especially urgent for infectious diseases, where rapid surveillance and detection are essential for controlling outbreaks and protecting patient health. As highlighted in the World Health Organization's 'Global Tuberculosis Report 2024' from October 2024, roughly 8.2 million individuals were newly diagnosed with tuberculosis in 2023, marking the highest figure since global monitoring started in 1995. This growing disease burden leads directly to higher volumes of post-market surveillance studies and clinical trial testing needed to verify new therapeutic solutions.

Concurrently, the expansion of R&D pipelines for biologics and biosimilars is transforming the testing services landscape. In contrast to conventional small-molecule drugs, large-molecule therapies such as monoclonal antibodies and cell therapies require highly specialized, sensitive, and expensive analytical testing methodologies to characterize their potency, purity, and immunogenicity. This shift forces manufacturers to outsource these intricate functions to accredited laboratories equipped with advanced instrumentation. According to the Drug, Chemical & Associated Technologies Association, July 2024, in the 'Innovation Scorecard', the U.S. FDA approved 17 new therapeutic biologics in 2023, which represented 31% of all new drug approvals, highlighting the industry's decisive pivot toward complex molecules. The financial magnitude of this sector is evident in the performance of leading service providers; according to Eurofins Scientific, February 2024, in the '2023 Full Year Results', the company reported total revenues of €6,515 million, reflecting the sustained industrial demand for outsourced analytical testing operations.

Market Challenge

A significant barrier impeding the progress of the Global Healthcare Testing Services Market is the shortage of skilled professionals. With medical device and pharmaceutical companies demanding increasingly sophisticated bioanalytical and analytical testing, the sector encounters a severe lack of qualified analysts equipped to handle these advanced techniques. This workforce gap results in operational inefficiencies, such as diminished sample processing capabilities and prolonged turnaround times. Consequently, service providers are compelled to restrict new client acceptance and push back project schedules, which directly inhibits revenue growth and market expansion initiatives.

Moreover, the substantial expense associated with hiring and keeping specialized personnel adds to the financial strain on testing laboratories. This labor constraint is supported by recent industry statistics. The American Society for Clinical Pathology's 2024 Vacancy Survey revealed that anatomic pathology departments experienced a vacancy rate of 28.5 percent, highlighting the acuteness of the labor shortage in essential testing domains. Such elevated vacancy rates hinder laboratories from maximizing the potential of their advanced infrastructure and instrumentation. Without an adequate workforce to facilitate operational scaling, testing service providers are unable to satisfy the growing global demand, effectively halting the broader advancement of the healthcare testing industry.

Market Trends

The Integration of Artificial Intelligence for Enhanced Diagnostic Precision is revolutionizing laboratory workflows by automating complex image analysis and improving clinical decision-making. Laboratories are increasingly deploying machine learning algorithms to process vast datasets in pathology and radiology, thereby reducing human error and identifying subtle biomarkers that traditional methods might miss. This technological shift is accelerating the commercial availability of smart diagnostic tools and facilitating faster regulatory clearances for software-based medical solutions. According to MedTech Dive, October 2024, in the article 'The number of AI medical devices has spiked in the past decade', the U.S. Food and Drug Administration authorized 221 AI or machine learning-enabled medical devices in 2023, marking a significant increase in the validation of these technologies for clinical use.

Simultaneously, the proliferation of Genomic and Precision Medicine Testing Services is moving the diagnostic focus from broad screening to individualized patient profiling. Distinct from standard bioanalytical testing used for characterizing drug substances, this movement emphasizes the identification of hereditary risks and the direction of targeted therapies for specific patients, especially in prenatal care and oncology. In response, service providers are broadening their offerings to encompass advanced molecular diagnostics that provide profound clinical insights and enable personalized treatment strategies. This strong demand is reflected in recent financial performance; Quest Diagnostics, in its 'Fourth Quarter and Full Year 2023 Financial Results' from February 2024, announced double-digit revenue growth in its advanced clinical segments, particularly hereditary genetics and prenatal testing, highlighting the market's uptake of specialized precision testing.

Key Market Players

• Eurofins Scientific (Ireland) Limited
• Thermo Fisher Scientific Inc.
• Microbac Laboratories, Inc.
• ARL Bio Pharma, Inc.
• EM Topco Limited
• Intertek Group plc
• Moderna, Inc.
• ZYUS Life Sciences Corp
• Alcami Corporation
• F. Hoffmann-La Roche Ltd

Report Scope

In this report, the Global Healthcare Testing Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Healthcare Testing Services Market, By Service Type

• Chemical Testing
• Microbiological Testing
• Toxicology Testing
• Stability Testing
• Others

Healthcare Testing Services Market, By Product Type

• Anti-viral Drugs
• HIV Drugs
• Fertility Drugs
• Anti-diabetic Drugs
• Respiratory Drugs
• Anticoagulants
• Medical Devices
• Pharmaceutical Packaging
• Others

Healthcare Testing Services Market, By Development Stage

• Preclinical
• Clinical
• Manufacturing

Healthcare Testing Services Market, By End User

• Pharmaceutical Industry
• Contract Research Organization
• Others

Healthcare Testing Services Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Healthcare Testing Services Market.

Available Customizations:

Global Healthcare Testing Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Healthcare Testing Services Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service Type (Chemical Testing, Microbiological Testing, Toxicology Testing, Stability Testing, Others)
  • 5.2.2. By Product Type (Anti-viral Drugs, HIV Drugs, Fertility Drugs, Anti-diabetic Drugs, Respiratory Drugs, Anticoagulants, Medical Devices, Pharmaceutical Packaging, Others)
  • 5.2.3. By Development Stage (Preclinical, Clinical, Manufacturing)
  • 5.2.4. By End User (Pharmaceutical Industry, Contract Research Organization, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Healthcare Testing Services Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service Type
  • 6.2.2. By Product Type
  • 6.2.3. By Development Stage
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Healthcare Testing Services Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service Type
      • 6.3.1.2.2. By Product Type
      • 6.3.1.2.3. By Development Stage
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Healthcare Testing Services Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service Type
      • 6.3.2.2.2. By Product Type
      • 6.3.2.2.3. By Development Stage
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Healthcare Testing Services Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service Type
      • 6.3.3.2.2. By Product Type
      • 6.3.3.2.3. By Development Stage
      • 6.3.3.2.4. By End User

7. Europe Healthcare Testing Services Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service Type
  • 7.2.2. By Product Type
  • 7.2.3. By Development Stage
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Healthcare Testing Services Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service Type
      • 7.3.1.2.2. By Product Type
      • 7.3.1.2.3. By Development Stage
      • 7.3.1.2.4. By End User
  • 7.3.2. France Healthcare Testing Services Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service Type
      • 7.3.2.2.2. By Product Type
      • 7.3.2.2.3. By Development Stage
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Healthcare Testing Services Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service Type
      • 7.3.3.2.2. By Product Type
      • 7.3.3.2.3. By Development Stage
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Healthcare Testing Services Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Service Type
      • 7.3.4.2.2. By Product Type
      • 7.3.4.2.3. By Development Stage
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Healthcare Testing Services Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Service Type
      • 7.3.5.2.2. By Product Type
      • 7.3.5.2.3. By Development Stage
      • 7.3.5.2.4. By End User

8. Asia Pacific Healthcare Testing Services Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service Type
  • 8.2.2. By Product Type
  • 8.2.3. By Development Stage
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Healthcare Testing Services Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service Type
      • 8.3.1.2.2. By Product Type
      • 8.3.1.2.3. By Development Stage
      • 8.3.1.2.4. By End User
  • 8.3.2. India Healthcare Testing Services Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service Type
      • 8.3.2.2.2. By Product Type
      • 8.3.2.2.3. By Development Stage
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Healthcare Testing Services Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service Type
      • 8.3.3.2.2. By Product Type
      • 8.3.3.2.3. By Development Stage
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Healthcare Testing Services Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Service Type
      • 8.3.4.2.2. By Product Type
      • 8.3.4.2.3. By Development Stage
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Healthcare Testing Services Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Service Type
      • 8.3.5.2.2. By Product Type
      • 8.3.5.2.3. By Development Stage
      • 8.3.5.2.4. By End User

9. Middle East & Africa Healthcare Testing Services Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service Type
  • 9.2.2. By Product Type
  • 9.2.3. By Development Stage
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Healthcare Testing Services Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service Type
      • 9.3.1.2.2. By Product Type
      • 9.3.1.2.3. By Development Stage
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Healthcare Testing Services Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service Type
      • 9.3.2.2.2. By Product Type
      • 9.3.2.2.3. By Development Stage
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Healthcare Testing Services Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service Type
      • 9.3.3.2.2. By Product Type
      • 9.3.3.2.3. By Development Stage
      • 9.3.3.2.4. By End User

10. South America Healthcare Testing Services Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service Type
  • 10.2.2. By Product Type
  • 10.2.3. By Development Stage
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Healthcare Testing Services Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Service Type
      • 10.3.1.2.2. By Product Type
      • 10.3.1.2.3. By Development Stage
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Healthcare Testing Services Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Service Type
      • 10.3.2.2.2. By Product Type
      • 10.3.2.2.3. By Development Stage
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Healthcare Testing Services Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Service Type
      • 10.3.3.2.2. By Product Type
      • 10.3.3.2.3. By Development Stage
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Healthcare Testing Services Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Eurofins Scientific (Ireland) Limited
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific Inc.
• 15.3. Microbac Laboratories, Inc.
• 15.4. ARL Bio Pharma, Inc.
• 15.5. EM Topco Limited
• 15.6. Intertek Group plc
• 15.7. Moderna, Inc.
• 15.8. ZYUS Life Sciences Corp
• 15.9. Alcami Corporation
• 15.10. F. Hoffmann-La Roche Ltd

16. Strategic Recommendations

17. About Us & Disclaimer